Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes (Q39101008)

9 September 2017

Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes (English)

1 reference

9 September 2017

1 reference

Stephen L Aronoff

1

1 reference

PubMed ID

28118069

9 September 2017

language of work or name

English

0 references

publication date

24 January 2017

1 reference

9 September 2017

Postgraduate Medicine

1 reference

9 September 2017

129

1 reference

9 September 2017

231-241

1 reference

9 September 2017

2

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

9 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Achievement of goals in U.S. diabetes care, 1999-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Contribution of fasting and postprandial hyperglycemia to hemoglobin A1c in insulin-treated Japanese diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Failure to reach target glycated a1c levels among patients with diabetes who are adherent to their antidiabetic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Glucose Metabolism and Regulation: Beyond Insulin and Glucagon

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Arguments for and against the role of glucose variability in the development of diabetes complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Exercise strategies to optimize glycemic control in type 2 diabetes: a continuing glucose monitoring perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Unrecognized Hypo- and Hyperglycemia in Well-Controlled Patients with Type 2 Diabetes Mellitus: The Results of Continuous Glucose Monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

The risk of dementia among persons with diabetes mellitus: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Meglitinide analogues in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

A review of the efficacy and safety of oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Evaluation of the Effects of Nateglinide on Postprandial Glycemia in Patients with Type 2 Diabetes mellitus: A Multicenter, Multinational, Non-Randomized, Non-Controlled Latin American Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Control of postprandial glucose levels with insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Therapy in the early stage: incretins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Incretin-based therapies: viewpoints on the way to consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

AACE/ACE comprehensive diabetes management algorithm 2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Postprandial hyperglycemia is highly prevalent throughout the day in type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1285191

10.1080/00325481.2017.1285191

21 January 2018

Identifiers

DOI

1 reference

release_fdzywifzmrg2xk5kbqjqa2ttfu

9 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fdzywifzmrg2xk5kbqjqa2ttfu

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

28118069

1 reference

PubMed ID

28118069